Literature DB >> 12074259

Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening.

David Cella1, Elizabeth A Hahn, Kelly Dineen.   

Abstract

INTRODUCTION: There has been increased recent attention to the clinical meaningfulness of group change scores on health-related quality of life (HRQL) questionnaires. It has been assumed that improvements and declines of comparable magnitude have the same meaning or value.
METHOD: We assessed 308 cancer patients with the Functional Assessment of Cancer Therapy (FACT) and a Global Rating of Change. Patients were classified into five levels of change in HRQL and its dimensions based upon their responses to retrospective ratings of change after 2 months: sizably worse, minimally worse, no change, minimally better, and sizably better. Raw score and standardized score changes on the FACT-G subscales and total score were then compared across different categories of patient-rated change.
RESULTS: The relationship between actual FACT change scores and retrospective ratings of change was modest but usually statistically significant (r: 0.07 to 0.35). Change scores associated with each retrospective rating category were evaluated to determine estimates of meaningful difference. Patients who reported global worsening of HRQL dimensions had considerably larger change scores than those reporting comparable global improvements. Although related to a ceiling effect, this remained true even after removing cases that began near the ceiling of the questionnaire. DISCUSSION: Relatively small gains in HRQL have significant value. Comparable declines may be less meaningful, perhaps due to patients' tendency to minimize personal negative evaluations about one's condition. This has important implications for the interpretation of the meaningfulness of change scores in HRQL questionnaires. Factors such as adaptation to disease, response shift, dispositional optimism and the need for signs of clinical improvement may be contributing to the results and should be investigated in future studies.

Entities:  

Mesh:

Year:  2002        PMID: 12074259     DOI: 10.1023/a:1015276414526

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  30 in total

Review 1.  Methods for assessing responsiveness: a critical review and recommendations.

Authors:  J A Husted; R J Cook; V T Farewell; D D Gladman
Journal:  J Clin Epidemiol       Date:  2000-05       Impact factor: 6.437

2.  Quality of life: the concept.

Authors:  D F Cella
Journal:  J Palliat Care       Date:  1992       Impact factor: 2.250

Review 3.  Interpretation of quality of life changes.

Authors:  E Lydick; R S Epstein
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

4.  Optimism, coping, and health: assessment and implications of generalized outcome expectancies.

Authors:  M F Scheier; C S Carver
Journal:  Health Psychol       Date:  1985       Impact factor: 4.267

5.  Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

Authors:  M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

6.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

Authors:  P Esper; F Mo; G Chodak; M Sinner; D Cella; K J Pienta
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

7.  Minimum important difference between patients with rheumatoid arthritis: the patient's perspective.

Authors:  G A Wells; P Tugwell; G R Kraag; P R Baker; J Groh; D A Redelmeier
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

8.  Psychological response of patients cured of advanced cancer.

Authors:  B J Kennedy; A Tellegen; S Kennedy; N Havernick
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

9.  Someone to live for: social well-being, parenthood status, and decision-making in oncology.

Authors:  S B Yellen; D F Cella
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

Review 10.  Measuring quality of life: 1995 update.

Authors:  D F Cella; A E Bonomi
Journal:  Oncology (Williston Park)       Date:  1995-11       Impact factor: 2.990

View more
  166 in total

1.  Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial.

Authors:  Vikki Ho; Romain Pasquet; Shaman Luo; Gang Chen; Paul Goss; Dongsheng Tu; Philip Lazarus; Harriet Richardson
Journal:  Breast Cancer Res Treat       Date:  2020-08-01       Impact factor: 4.872

Review 2.  The clinical importance of quality-of-life scores in patients with skull base tumors: a meta-analysis and review of the literature.

Authors:  Moran Amit; Avraham Abergel; Dan M Fliss; Ziv Gil
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

3.  The quality of life of parents of children with atopic dermatitis: interpretation of PIQoL-AD scores.

Authors:  D M Meads; S P McKenna; K Kahler
Journal:  Qual Life Res       Date:  2005-12       Impact factor: 4.147

Review 4.  The clinical significance of adaptation to changing health: a meta-analysis of response shift.

Authors:  Carolyn E Schwartz; Rita Bode; Nicholas Repucci; Janine Becker; Mirjam A G Sprangers; Peter M Fayers
Journal:  Qual Life Res       Date:  2006-09-26       Impact factor: 4.147

5.  Minimal clinically important differences in the EORTC QLQ-BN20 in patients with brain metastases.

Authors:  Erin Wong; Liying Zhang; Marc Kerba; Palmira Foro Arnalot; Brita Danielson; May Tsao; Gillian Bedard; Nemica Thavarajah; Paul Cheon; Cyril Danjoux; Natalie Pulenzas; Edward Chow
Journal:  Support Care Cancer       Date:  2015-02-10       Impact factor: 3.603

6.  Development and initial evaluation of a telephone-delivered, behavioral activation, and problem-solving treatment program to address functional goals of breast cancer survivors.

Authors:  Kathleen D Lyons; Jay G Hull; Peter A Kaufman; Zhongze Li; Janette L Seville; Tim A Ahles; Alice B Kornblith; Mark T Hegel
Journal:  J Psychosoc Oncol       Date:  2015-02-10

7.  A randomized trial of weekly symptom telemonitoring in advanced lung cancer.

Authors:  Susan E Yount; Nan Rothrock; Michael Bass; Jennifer L Beaumont; Deborah Pach; Thomas Lad; Jyoti Patel; Maria Corona; Rebecca Weiland; Katherine Del Ciello; David Cella
Journal:  J Pain Symptom Manage       Date:  2013-11-07       Impact factor: 3.612

8.  Factors affecting health related quality of life of rectal cancer patients undergoing surgery.

Authors:  C Krishnan Nair; P S George; K S Rethnamma; R Bhargavan; S Abdul Rahman; A P Mathew; M Muralee; K Cherian; P Augustine; M I Ahamed
Journal:  Indian J Surg Oncol       Date:  2014-10-16

9.  Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years.

Authors:  Karen L Syrjala; Brenda F Kurland; Janet R Abrams; Jean E Sanders; Julia R Heiman
Journal:  Blood       Date:  2007-09-18       Impact factor: 22.113

10.  Responsiveness of 8 Patient-Reported Outcomes Measurement Information System (PROMIS) measures in a large, community-based cancer study cohort.

Authors:  Roxanne E Jensen; Carol M Moinpour; Arnold L Potosky; Tania Lobo; Elizabeth A Hahn; Ron D Hays; David Cella; Ashley Wilder Smith; Xiao-Cheng Wu; Theresa H M Keegan; Lisa E Paddock; Antoinette M Stroup; David T Eton
Journal:  Cancer       Date:  2016-10-03       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.